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Abstract:  6 
There remains considerable interest in developing methods for the targeted delivery of nitric 7 
oxide and other small molecule bioregulators such as carbon monoxide to physiological targets.  8 
One such strategy is to use a "caged" NO that is "uncaged" by excitation with light.  Such 9 
photochemical methods convey certain key advantages such as the ability to control the timing, 10 
location and dosage of delivery, but also have some important disadvantages, such as the 11 
relatively poor penetration of the ultraviolet and visible wavelengths often necessary for the 12 
uncaging process.  Presented here is an overview of ongoing studies in the author's laboratory 13 
exploring new photochemical NO precursors including those with nanomaterial antennas 14 
designed to enhance the effectiveness of these precursors with longer excitation wavelengths.     15 
 16 
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Introduction: 21 
 The purpose of this article is to provide an overview of studies in my laboratory relevant to 22 
the delivery of small molecule bioregulators to physiological targets.  Our approach and that of 23 
others to more controlled, specific delivery is to develop stable compounds that release the 24 
molecule in question only when triggered by an external signal, namely photo-excitation of an 25 
appropriate precursor.  The precursor is in principle inactive, hence the bioactive agent of interest 26 
is "caged", but upon photoexcitation, the latter species is released ("uncaged") (Scheme 1).  27 
Although we have focused primarily on the delivery of nitric oxide [1-3],  these strategies should 28 
apply to other chemotherapeutic molecules such as carbon monoxide, which has also drawn our 29 
recent attention [4-6]. For CO, the term "photoCORM" (for photoactivated CO releasing moiety) 30 
has been coined [4] to designate a photochemical CO precursor, and, while no such term has 31 
caught on with NO precursors, one now hears "photoNORM" used occasionally. The advantage 32 
of photo-activation is that the external signal allows one to define the location and timing of the 33 
NO delivery.  Furthermore, since the amount of photochemical reaction is a function of the 34 
quantity of light delivered to the desired target, this allows one also to define the dosage of the 35 
release.  Although the present manuscript is focused largely upon our own studies, it should be 36 
noted that there is a growing interest in applying photochemical methods to the uncaging of NO 37 
[7-12] and CO [5,13-14] as well as other bioregulators [15]. 38 
Scheme 1: Cartoon illustrating the photochemical uncaging of a bioactive substance which in the original "caged" 39 
form (presumably some type of conjugate) is not active. 40 
   41 
 Various rationales for controlled NO delivery range include its cardiovascular effects, 42 
antibacterial properties and potential roles in generating apoptosis in tumor cells.  With regard to 43 
cancer therapy, one problem is that, although high localized levels of NO can induce cell 44 
apoptosis, low levels of NO may induce tumor growth instead [16].  Thus, it is essential to have 45 
very careful control over the dosage delivered.  In this context our interest in the 46 
phototherapeutic NO delivery draws from the view that this should be synergistic with other 47 
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forms of treatment.   For example, it has been shown that NO increases the sensitivity of tumor 48 
cells to radiation therapy [17] and chemotherapy [18]. The hypoxic regions of malignant tumors 49 
are much more radio-resistant than is normoxic tissue, therefore one should be able to reduce the 50 
collateral damage from radiotherapy by developing strategies to increase the sensitivity of the 51 
targeted tissue. Hypoxia radiation resistance may be alleviated by introducing a sensitzer and/or 52 
a vasodilator to increase tissue oxygenation; both are roles played by NO.  Radiation 53 
sensitization requires NO concentrations near 1 µM [17], but vasodilation is triggered at much 54 
lower concentrations of NO [19], so that even at very low concentrations, exogenously delivered 55 
NO may indirectly enhance the radiation killing of tumor tissue.   56 
 An example of such radiation sensitization is illustrated in Figure 1.  In this case, four 57 
different samples of V-79 (Chinese hamster lung fibroblast cells) were subjected to g-radiation 58 
from a Co-60 source in an equivalent manner and the resulting cell viability evaluated [20].  One 59 
cell sample was under aerobic conditions, and it is easily seen that less than 1% of the cells were 60 
stlll viable after a g-radiation dose of ~11 Gy.  In contrast, hypoxic cells proved to be much more 61 
resistant, with radiation doses exceeding 25 Gy to achieve a comparable effect.  The same cells 62 
incubated with a 500 µM solution of the photochemical NO donor Roussin's red salt 63 
Na2[Fe2S2(NO)4] (RRS, see below) showed no enhancement of the radiation effect, but when a  64 
 65 
Figure 1.  Survival of V79 Chinese hamster lung cells exposed to g-radiation under hypoxic conditions without 66 
(open circles) or with 500 mM Roussin’s red salt (RS) under simultaneous irradiation with white light (closed 67 
circles) or in the dark (open squares). The dashed line on the plot indicates the response of V79 cells exposed to g-68 
radiation under normoxic conditions (WL refers to white light illumination. (Adapted with permission from ref. 20 69 
Copyright 1997 American Chemical Society.) 70 
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 71 
comparable sample was also illuminated with light from a simple 35 mM projector, a marked 72 
enhancement of the radiation damage was apparent.  Given that these results paralleled those 73 
observed when other NO donors were utilized, it was concluded that the photochemical release 74 
of NO from the RRS is responsible for the observed sensitization [20]. 75 
 With regard to carbon monoxide, it has long been known that CO is produced endogenously 76 
by heme oxygenases, and there are newer developments indicating that endogenously and/or 77 
exogenously produced CO may be cytoprotective during inflammation, promote wound healing, 78 
and have signaling properties [for examples: 21-22].  In addition various CO donors have been 79 
shown in animal studies to be effective in alleviating ischemia/reperfusion (I/R) injury in various 80 
organs and tissues [for examples: 23-25]. 81 
 Strategies for and problems with developing methodologies for photochemical CO and NO 82 
release show certain parallels. One property desirable for a photochemical precursor would be 83 
solubility in aqueous solution or (perhaps) in a medium such as aqueous dimethylsulfoxide 84 
(DMSO) that is commonly used for drug delivery.  Another would be reasonable stability in 85 
aerated aqueous media at physiological temperatures and other conditions typical to living 86 
organisms.  A third would be photoreactivity at wavelengths where the transmission of light is 87 
optimal (Figure 2) [26].  Penetration depth of light into tissue is strongly wavelength dependent.  88 
 89 
Figure 2:  Absorption properties of various tissue components showing the windows in the near-infrared spectral 90 
region   (adapted from ref. 26 with permission from the Nature Publishing Group.  Original figure provided by Dr. 91 
A.  Smith of Emory University ) 92 
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It is shallow for ultraviolet light, but improves for longer visible wavelengths and tissue 93 
penetration reaches its deepest values in the near infrared (NIR) spectral region (~700-1100 nm). 94 
 Photochemical activation at these longer wavelengths might be accomplished by using 95 
antenna chromophores having high extinction coefficients at the desired wavelengths (Scheme 96 
2).  However, such an antenna can be an effective photosensitizer only if there are acceptor states 97 
on the precursor molecule having the appropriate energies.  A more ambitious approach would 98 
be to utilize an antenna with a high two-photon excitation (TPE) cross-section in the NIR.  For 99 
such a system, excitation with a NIR laser could generate high-energy photosensitizer states that 100 
can access reactive excited states of the photochemical precursor.  We will discuss this approach 101 
below. 102 
 It should be noted that, while these photochemical precursors are designed to release the 103 
caged bioactive substance upon irradiation with light, a remaining molecular fragment is also 104 
produced. These should be identified and characterized along with any secondary products 105 
readily formed by subsequent reaction with the medium.  Furthermore, the physiological 106 
properties of these other photoproducts need to be examined to confirm whether the perceived 107 
physiological effect is due to release of the caged species or to the unforeseen activity of other 108 
species directly or indirectly generated. Lastly, as in the development of any new therapeutic 109 
strategy, the acute and long-term toxicity of all these compounds must be evaluated.   110 
Scheme 2. Single- or two-photon excitation of an antenna/photochemical precursor conjugate leading to release of 111 
XY (CO or NO).  D is the donor molecule acting as an antenna to absorb light give an excited state D* that 112 
undergoes energy transfer to the acceptor molecule LxM-XY, which is represented here as a metal complex that 113 
releases X-Y after the energy transfer step.    114 
 115 
 116 
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 In photochemical research, the efficiency noted above is called the quantum yield (FP, eq. 1), 117 
which is the amount (in moles) of the desired chemical reaction DP per Einstein of light absorbed 118 
Dhn (one Einstein = 6.023 x 1023 photons) by the photoactive precursor (eq. 1). 119 
FP  =  DP/Dhn       (1) 120 
For single photon excitation (SPE), DP should be a linear function of Dhn.  Generally Fp is 121 
determined for photoexcitation at a specific wavelength, since it may be wavelength dependent.  122 
 When the goal is to perturb a dynamic physiological system by photochemical release of a 123 
bioactive substance, the uncaging rate may be of greater interest.  This is defined by (eq. 2), 124 
d[P]/dt  =  FPIa         (2) 125 
where d[P]/dt is the rate product formation in moles per unit time per unit volume and I  is the 126 
intensity of the light absorbed by the precursor in Einsteins per unit time per unit volume at the 127 
excitation wavelength.  I  is a function both of the incident light intensity Io and the ability of the 128 
compound to absorb at the wavelength of excitation.  For a solution phase system where the 129 
photoreactant is the only species absorbing the incident light, 130 
    I  =  Io(1-10-Abs(l))       (3) 131 
where Abs(l) is the solution absorbance at the excitation wavelength lirr and equals the product 132 
of the molar concentration of the photoactive species (c), the molar extinction coefficient (el, in 133 
L moles-1 cm-1) at the wavelength l and the path-length of the solution cell (in cm).  Thus, the 134 
rate of photoproduct formation under SPE at a particular wavelength will be directly proportional 135 
to I0 and to FP and will be a more complex function of c and el.   In this context, efficient 136 
photochemical delivery to physiological targets should be more favorable with precursors that 137 
absorb strongly at the desired excitation wavelength(s) lex.  If the product c ✕ el is sufficiently 138 
large, all the light is absorbed and the photoreaction rate becomes independent of both terms.  139 
However, this scenario is unlikely in a targeted tissue, and absorption by other chromophores or 140 
scattering of the light beam can have a significant effect on Ia.  When polychromic light is used, 141 
the photochemical rate is the integral of FP ✕ Ia over the excitation wavelengths, noting that FP 142 
may be, and Ia certainly will be, functions of lirr. 143 
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 The ensuing sections will discuss first the use of typical single photon excitation methods 144 
with various nitric oxide precursors ("caged NO"), including those with antenna chromophores 145 
to enhance the absorption of light.  We will then examine the potential applications of multi-146 
photon excitation methods to facilitate the photochemistry of such precursors using tissue 147 
penetrating near infrared (NIR) light. 148 
 149 
Photochemical NO precursors:   150 
 Scheme 3 illustrates several representative types of transition metal complexes that release 151 
NO upon photoexcitation.  Two of these (a and b) are metal nitrosyls, where the nitric oxide is 152 
caged by coordination to a transition metal center [20,27]. For such complexes, a commonly 153 
observed photochemical process is cleavage of the metal-NO bond to give neutral NO  (rather  154 
Scheme 3.  Examples of photochemical NO release from compounds representative of those under study.  a. 155 
Roussin's red salt anion.  b. A ruthenium salen nitrosyl complex.  c. The Cr(III) nitrito complex trans-156 
Cr(cyclam)(ONO)2+  (cyclam = 1,4,8,11-tetrazacyclotetradecane) 157 
 158 
  159 
 160 
   161 
than the ionic species NO– or NO+).  The third example is an O-nitrito complex [28] where the 162 
NO is caged by bonding to another oxygen. In this case, NO is released by homolytic cleavage of 163 
the MO-NO bond.  Since the nitrogen of nitrite ion is formally in the +3 oxidation state and that 164 
of NO is formally +2, the extra electron must come from the metal center.  Thus, for the example 165 
shown, the release of NO is accompanied by the oxidation of the metal, in this case a 166 
chromium(III).  167 
 8 
 The iron sulfur nitrosyl anionic cluster, Rousin's red salt anion (RRS) was the NO precursor 168 
used to demonstrate that photochemically released NO enhances the ability of g-radiation to kill 169 
hypoxic cultured cells as illustrated in Figure 1. RRS absorbs broadly in the visible and this 170 
radiation sensitization experiment proved quite successful using a simple slide projector as the 171 
white light source.  However, RRS is only modestly stable in aerobic aqueous media, so in 172 
search of more stable analogs, our studies turned to the red salt esters (RSE) that are prepared by 173 
the reaction shown in eq. 4.    174 
  (4) 175 
These RSE, even with simple ligands such as a benzyl or ethyl group, qualitatively displayed 176 
greater stability as well as more efficient NO release, since photolysis in aerated aqueous 177 
solution led to the release of all four NO's (eq. 5) [29].     178 
      (5) 179 
 Furthermore, variations of this synthetic procedure could be used to build RSE's with R- 180 
groups having strongly absorbing chromophores.  Two such examples are PPIX-RSE and Fluor-181 
RSE, where the pendant groups are derivatives of protoporphyrin XI [30] and of fluorescein [31], 182 
respectively.  These pendant chromophores are much more efficient at gathering light than is the 183 
Fe2S2(NO)4 cluster itself, hence they can serve as antennas that are first excited then undergo 184 
energy transfer to the cluster to photosensitize NO release. 185 
 186 
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 The photochemistry of both PPIX-RSE and Fluor-RSE clearly demonstrate this antenna 187 
effect. For example, dilute solutions (10 µM), photo-decomposition of the PPIX-RSE conjugate 188 
excited at longer visible wavelengths (lirr 546 nm) occurred at much higher rates than did the 189 
simpler ester Fe2(µ-SEt)2(NO)4 (Et-RSE) under otherwise identical conditions [30]. The 190 
enhanced rate of NO release was largely attributed to the more efficient light absorption (Ia) by 191 
the tethered PPIX owing to the strong porphyrin Q-bands in this region. In addition, the 192 
fluorescence that is characteristic of the PPIX chromophore was largely quenched (Figure 3), 193 
presumably as the result of energy transfer to the RRS cluster.  Thus, attaching an antenna to the 194 
red salt cluster enhances the rate of NO production via the visible light photoreaction as 195 
intended.  However, the quantum yields for both PPIX-RSE and Et-RSE are relatively low at this 196 
excitation wavelength.  197 
Figure 3.  The fluorescence spectra of free PPIX and the red salt ester PPIX-RSE at comparable concentrations and 198 
under identical conditions, showing that the fluorescence from the latter is about 85% quenched by attachment to the 199 
Fe/S/NO cluster.  Emission lifetime measurements confirm that this quenching is likely due to energy transfer to the 200 
cluster.  (Reprinted with permission from ref 30. Copyright 2004, American Chemical Society.) 201 
 Fluor-RSE with two pendant fluorescein dye units represents the second generation of such 202 
Roussin's esters. This compound is moderately soluble in buffered aqueous solutions, and like 203 
PPIX-RSE, the characteristic fluorescence of the antennas is ~85% quenched upon linking to the 204 
Fe/S/NO cluster.  The photochemistry of Fluor-RSE in aqueous media parallels that seen for 205 
other esters. Consistent with eq. 5, all four NOs were released with a ΦNO of 0.014 when 206 
irradiated at 436 nm [31]. 207 
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 The metal nitrito complex trans-Cr(cyclam)(ONO)2+ (called "CrONO" in our lab) has several 208 
attractive features as a potential therapeutic photochemical NO precursor.  First, it is thermally 209 
stable under physiologically relevant conditions (pH 7.4, normoxic aqueous buffer at 37 oC) and 210 
limited cell culture studies indicated no toxicity [32].  Second, CrONO is photoactive, and 211 
displays a substantial quantum yield for the release of NO according to the reaction shown in 212 
Scheme 3c over the wavelength range 365-536 nm.  The quantum yield measured by spectral 213 
changes is 0.25-0.30 moles Einstein-1 and is essentially independent of the excitation wavelength 214 
lex.  Direct measurement of NO release using a Sievers Nitric Oxide Analyzer (NOA) gave an 215 
equivalent quantum yield (FNO = 0.25) when the trapping agent was GSH.  However, the visible 216 
range absorption bands leading to this photochemistry are metal centered d-d bands (sometimes 217 
called ligand field bands) and these have very low extinction coefficients el, since they represent 218 
symmetry forbidden transitions.  As a consequence, the rates of NO generation are relatively low 219 
unless the concentration of CrONO and/or the intensity of the excitation light source is high (see 220 
eqs. 2 and 3)  221 
Another feature of the CrONO system is that there is a relatively fast back reaction (kNO = 3.1 222 
x 106 M-1 s-1 in 298 K aqueous solution) to regenerate the coordinated nitrite [28].  In such a case, 223 
it may be necessary to trap the metal-containing fragment in order to ensure a substantial net 224 
yield of NO release.  The CrIV(O) intermediate formed by the reaction illustrated in Scheme 3c is 225 
subject to both oxidative and reductive trapping (Scheme 4) [32,33]. When either an oxidant 226 
such as O2 or a reductant such as glutathione (GSH) is present to trap the Cr(IV) intermediate, 227 
permanent photochemistry is observed. Thus CrONO is an effective NO donor under a variety of 228 
conditions, but should be especially effective in hypoxic tissue where the Cr(IV) would be  229 
Scheme 4: The reversible labilization of NO from CrONO.  The net production of NO is effected by the trapping of 230 
the Cr(IV) intermediate by oxygen in aerobic media or by GSH in a more reducing environments.  The reaction with 231 
O2 in aerobic media is complicated by the formation of O2– which can trap a substantial fraction of the NO to give 232 
peroxoxynitrite (adapted from ref 33).   233 
 234 
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trapped by GSH or other reductants. 235 
 Despite the small molar extinction coefficients of CrONO, it is notable that the NO 236 
photochemically released from even quite dilute solutions is sufficient to activate the enzyme 237 
soluble guanylyl cyclase (s-GC) and to effect vasorelaxation in porcine arteries (Figure 4).  Both 238 
phenomena, of course, reflect the great sensitivity of s-GC activation to NO [19]; nonetheless 239 
these observations demonstrate the potential applicability of the photochemical technique for 240 
delivering bioactive molecules to desired targets.  For example, the experiments summarized by 241 
Figure 4 clearly show that the porcine arterial ring relaxation can be attributed to NO generated 242 
by photolysis of CrONO, not to other photoproducts nor to the complex itself.  Under these 243 
conditions, the IC50 for solutions of CrONO is ~ 320 nM [33].   244 
 245 
Figure 4:  Effect of CrONO on vasorelaxation in endothelium-denuded porcine coronary arterial rings.  Black 246 
diamonds: in the dark; Green triangles: ambient light; Blue circles:  exposed to 470 nm LED; . Red open triangles: 247 
vasodilator effect of light activated CrONO was abolished the sGC inhibitor, ODQ is present.  Purple squares:  a 248 
product solution of photolyzed CrONO had no effect in the dark.  (Figure adapted from ref. 33.) 249 
 250 
Thus, CrONO is a compound that satisfies most criteria for a photochemical NO precursor 251 
with the exception of its very low absorptions at desired longer visible wavelengths.  To address 252 
this limitation, we have therefore turned our efforts to attaching various chromophores to 253 
CrONO-like systems to serve as antennas for enhancing light absorption and increasing rates of 254 
photo-induced NO production.  Our first studies in that regard focused on organic dyes linked via 255 
the macrocyclic cyclam ring, such as illustrated by Scheme 5 (top).  Such conjugates clearly 256 
demonstrate that attachment of such a dye increases the rate of NO production from dilute 257 
solutions owing to the greater absorption cross sections of the pendant antenna [34].     258 
 259 
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Scheme 5. Top: Ilustration of a pendant pyrene type chromophore acting as an antenna to collect light and 260 
photosensitize the release of NO from a CrONO type center [32].  Bottom: Analogous photosensitization of NO 261 
release from CrONO using a water-soluble CdSe:ZnS core:shell semiconductor quantum dot as the antenna [34-36].   262 
 263 
 264 
 It was in this context that we decided to consider semiconductor quantum dots (QDs) as 265 
potential photosensitizers. The first system we explored consisted of CdSe:ZnS core:shell QDs 266 
with a core diameter of ~3.8 nm that had been ligand exchanged to decorate the surface with 267 
dihydrolipoic acid (DHLA) in order to impart water solubility at physiological pH [35,36].  In 268 
aqueous solution, these QDs displayed a photoluminescence (PL) centered at 570 nm, that was 269 
progressively quenched with increasing concentrations of added CrONO.  More importantly, 270 
when a solution was prepared containing these QDs (100 nM) and CrONO (200 µM) and was 271 
photolyzed, substantially more NO was generated than from analogous solutions containing only 272 
CrONO at the same concentration.   Subsequent studies confirmed that both the PL quenching 273 
and the sensitized NO production can be attributed to an energy transfer mechanism from the 274 
excited QDs to CrONO (Scheme 5 bottom)  [36].  The interaction between the CrONO cations 275 
and the water-soluble QDs would appear to involve electrostatic assemblies formed by ion 276 
pairing at the anionic QD surfaces.  We do not expect such assemblies to be stable under 277 
physiological conditions, hence we are developing synthetic protocols to attach CrONO and 278 
other photochemical nitric oxide precursors to the QD surfaces via strong covalent bonds.  279 
 280 
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Multi-photon excitation using near-infra red light. 281 
 The reactive excited states of otherwise attractive precursors are often too high in energy to 282 
be accessed by typical single photon excitation (SPE) using excitation at longer visible 283 
wavelengths or in the NIR therapeutic window. In such a case, even the attachment of an antenna 284 
with strong absorption bands does not help, since there would be insufficient energy to sensitize 285 
the population of these high energy states.  In principle this limitation can be addressed by using  286 
multi-photon excitation, where the summed energy of several NIR quanta are sufficient to 287 
generate the energies necessary to trigger the desired uncaging. Two different multi-photon 288 
excitation approaches have been explored in our laboratory: (a) two photon excitation (TPE) 289 
which involves simultaneous absorption of two quanta of light, and (b) energy transfer 290 
upconversion (ETU) which can be obtained by sequential absorption processes.  TPE is 291 
illustrated in Scheme 6, while ETU is discussed below  292 
 The rates of photochemical processes initiated by simultaneous or sequential multi-photon 293 
absorption processes typically will have a non-linear dependence on the light intensity Io, which 294 
is different from the behavior of SPE stimulated processes (eqs. 2 & 3). For example, the 295 
probability of TPE is proportional to I2, the square of the incident light intensity, if a single 296 
source is utilized.  Thus, TPE induced photoreaction will be fastest at the focal plane of the light 297 
source.  This therefore offers the possibility of 3-D spatial resolution, a property that is 298 
extensively exploited in imaging [37,38] and offers interesting possibilities in phototherapy [39]. 299 
Scheme 6. TPE model for achieving higher energy excited states (ES) using muti-photon excitation.  TPE involves 300 
simultaneous absorption of two photons to generate an ES (E2) having the summed energy of the two photons. The 301 
resulting ES may undergo emission, may react to give products or undergo energy transfer to another chromophore.  302 
 303 
 Two photon excitation and absorption: The selection rules for TPE are different from those 304 
for SPE; the former is allowed only between two states that have the same parity, while the latter 305 
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requires a parity change.  Chromophores with high two photon absorption  cross sections in the 306 
NIR excitation region include extensively p-conjugated molecules especially that are 307 
quadrupolar with electron-donor and -acceptor units arranged symmetrically with respect to the 308 
center [40,41]. Semi-conductor quantum dots are also TPE chromophores with two photon 309 
absorption cross sections as large as 104 GM seen for the commonly studied cadmium selenide 310 
core or CdSe/ZnS core/shell QDs  [42,43].1   311 
 Our first TPE study involved the Roussin's red salt ester PPIX-RSE that we had previously 312 
shown to be photoactive to NO release when subjected to SPE at mid-visible wavelengths [29]. 313 
Wecksler et al tested this possibility by subjecting a solution of PPIX-RSE to 810 nm NIR 314 
excitation with 100 fs pulses from a Ti/sapphire laser [44].  These intense NIR pulses led to weak 315 
phosphorescence from PPIX-RSE (lmax 632 nm) accompanied by NO generation. Both the NO 316 
release and emission provided clear evidence that the higher energy ESs responsible for these 317 
phenomena were being populated by multiphoton excitation, even though the two photon 318 
absorption cross-section (d) of PPIX is known to be quite low (~2 GM). 319 
 320 
Figure 5. TPE of Fluor-RSE.  Log [NO]/s versus Log P plot, where [NO]/s is the concentration of NO released in 321 
30 s under 800 nm excitation, and P is the average power (in megawatts) of the pulsed laser (100 fs pulses at 80 322 
MHz) which is proportional to the pulse intensity I.   The slope = 1.8 ±  0.15.  (adapted from ref. 31) 323 
 324 
                                               
1 The GM is the unit of two photon cross sections, and 1 GM = 10-50 cm4 s photon-1.  This is named in honor of 
Maria Goeppert-Mayer, who first proposed theoretically the concept of two photon excitation, a concept that was 
not confirmed until decades later.  
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Wecksler extended these studies to two other red salt esters, Fluor-RSE and AFX-RSE.  In 325 
both cases the pendant dyes have been shown to have much higher d values [31,45].  In both 326 
cases, the fluorescence properties of the excited state species formed after TPE at 800 nm were 327 
the same as those observed upon SPE at 436 nm, indicated that the same states are formed 328 
regardless of the method of excitation.  In each case, the fluorescence was markedly attenuated 329 
from that of analogous chromophores without the Fe/S/NO cluster, and this was accompanied by 330 
NO release.  When Fluor-RSE was irradiated with 800 nm light from the ultrafast laser system, a 331 
log/log plot of the NO generated vs. the excitation intensity was linear with a slope of 1.8 ± 0.2 332 
(Figure 5), consistent with the squared dependence on excitation intensity as expected for a 333 
photochemical process initiated by TPE [31].   334 
 335 
AFX-RSE 336 
 337 
 A subsequent study by Prasad and coworkers [46] described another RSE derivative 338 
Fe2(NO)4(µ-SR')2, where R'S- is the chromophore oligo-phenylene vinylene amine with a large 339 
d, conjugated to tetra(ethylene glycol) ethers to improve aqueous solubility.  Both SPE at 365 nm 340 
and TPE at 775 nm led to NO release as well as light dependent cytoxicity in Hela and Cos-7 341 
cancer cell cultures.  As expected the magnitude of the effect was greater in the SPE experiments 342 
owing to the greater flux of NO generated with direct UV excitation, although this advantage  343 
 344 
R'S– 345 
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would be attenuated in tissue systems owing to the dramatically different transmission properties 346 
of the two wavelengths.  This and the other studies with Roussin's red salt esters suggest the 347 
feasibility of using two photon excitation techniques for the delivery of NO to physiological 348 
sites, although much more needs to be done. 349 
 NO uncaging using LnIII-doped NIR upconverting nanoparticles (UCNPs):  Energy transfer 350 
upconversion (ETU) involving the sequential absorption of photons is another process that is 351 
nonlinear with regard to the intensity of the excitation source.  Luminescent UCNPs based on the 352 
lanthanoid ions can be used in such devices owing to the relatively long lifetimes of the f-f 353 
excited states [47].  Typically, a LnIII ion such as Yb3+ is the sensitizer that absorbs the NIR light 354 
and transfers this energy to an acceptor LnIII ion such as Er3+, Tb3+, or Tm3+ as illustrated in 355 
Figure 6 [48].  Continued excitation of the sensitizer Yb3+ leads to further energy transfer to the 356 
long-lived acceptor states to populate new, higher energy states from which emission (or 357 
emissions) occurs at considerably shorter wavelengths than the initial NIR source. The absolute 358 
and relative intensities of the upconverted visible or ultraviolet wavelength emissions will 359 
depend nonlinearly on the intensity of the pumping process. 360 
 361 
Figure 6.  Energy transfer upconversion (ETU) model for achieving higher energy excited states using muti-photon 362 
excitation. Pumping the sensitizer center (Yb3+) with  980 nm NIR light gives an ES (2F5/2) that can undergo energy 363 
transfer to an acceptor (Er3+) to give a long lived ES. Continued excitation of the sensitizer Yb3+ followed by energy 364 
transfer to Er3+ gives the higher energy ES from which several visible range emissions occur. Figure adapted from 365 
ref. 48. 366 
 17 
 The energies of 4f-4f electronic transitions are primarily defined by spin and electronic 367 
repulsion terms and show little sensitivity to the chemical environments of the LnIII cations [45].  368 
However, 4f-4f excited state lifetimes are quite sensitive to the environment, since collisions and 369 
vibronic coupling contribute strongly to non-radiative deactivation. If an appropriate solid matrix 370 
is used, collisional contributions are eliminated and the phonon-coupling pathways are 371 
suppressed to give longer lifetimes and stronger emissions [49].  Various host crystals such as 372 
NaGdF4, NaYF4, LaPO4, YF3, or Y2O3 have been used, and the b-phase (hexagonal) NaYF4 373 
lattice has particularly favorable properties [50,51].  The large surface areas of nanoparticles 374 
exposes a sizable fraction of the lanthanoid emitters to solvent quenching, so these surface ions 375 
are protected from such environmental effects by growing a shell of the host material around the 376 
UCNP [52-54].  In addition, silica or polymer coatings can be introduced [55].  The emission 377 
properties of a Yb3+/Er3+ nanomaterial is illustrated in Figure 7.  The narrow line and long 378 
lifetime luminescence as well as the photostability of such UCNPs make them well suited for 379 
biological imaging. 380 
 381 
Figure 7. Upconversion emission spectra silica coated UCNPs, Yb/Er (20/2%) in b-NaYF4 core with a NaYF4 shell 382 
in aqueous solution.  The spectra resulting from three different powers (0.58, 0.96 and 1.36 W) of a 980 nm diode 383 
laser excitation source indicate a non-linear response of emission intensity to excitation power. A log/log plot of 384 
emission intensity at 550 nm vs. power is linear with a slope of 1.63.  385 
 There have been limited studies with regard to using NIR excitation of UCNPs for uncaging 386 
reactions.  Several years ago Carling et al. [56] showed that 980 nm photolysis of NaYF4:Yb/Tm 387 
(30/0.5%) nanoparticles surface loaded with 3’,5’-(carboxymethoxy)benzoin acetate (CBA) led 388 
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to cleavage (uncaging) of acetate from this UV absorbing organic chromophore.  Similarly, Y. 389 
Yang et al. [57] utilized upconverted Tm3+ UV emission from NaYF4:Yb/Tm (20/0.2%):NaYF4 390 
core:shell UCNPs  to release d-luciferin conjugated to a thiolated silica layer in C6 glioma cells 391 
and in living mice.  The latter experiment demonstrates how NIR excitation of UNCPs might be 392 
used to deliver bioactive molecules to living systems. 393 
  We have recently shown [58] that NIR excitation of assemblies based on 394 
NaYF4:Yb/Er(20/2%):NaYF4  core:shell UCNPs can trigger NO uncaging from Roussin's black 395 
salt anion Fe4S3(NO)7– (RBS, Na+ salt). Solutions of RBS alone are photoactive under 396 
UV/visible excitation (eq. 6)  [59,60] but are not affected by NIR irradiation.   Notably the strong  397 
             (6) 398 
absorption bands of RBS overlay the visible range emissions of b-NaYF4:Yb/Er UCNPs.  Two 399 
RBS/UCNP combinations were prepared.  One involved b-NaYF4:Yb/Er (20/2%):NaYF4 400 
core:shell UCNPs (average diameter 20 nm) coated with a silica layer (~10 nm) surface modified 401 
with cationic -NH3+ groups to attract the RBS anions.  NIR (980 nm) irradiation of these 402 
suspended in a solution of NaRBS resulted in the NO generation as detected by a GE Nitric 403 
Oxide Analyzer (NOA).  NO output was linear with the irradiation time at constant power but 404 
showed a non-linear response to systematic increases in laser power from 1 to 4.5 W as expected.  405 
 The second approach is illustrated in Scheme 7.  A mesoporous silica layer was added to the 406 
analogous UCNPs to give nanomaterials with a porous layer.  These were then impregnated with 407 
RBS after which they were coated with poly(allylamine hydrochloride). The RBS remained 408 
encapsulated after washing and isolating these nanocarriers of caged NO. However, NIR 409 
irradiation released NO [58].  The quantum efficiencies for both systems were small, owing to 410 
the low photoreactivity of RBS and the low upconversion yield.  Nonetheless, these proof-of-411 
concept experiments show that UCNPs offer the opportunity to deliver NO to specific targets 412 
 19 
using NIR light generated by a relatively inexpensive diode laser.  One can anticipate that the 413 
photonic efficiencies will be improved, especially in the context that these nanocarriers offer the 414 
opportunity for targeted uncaging of NO at therapeutically relevant sites [51].  415 
 416 
Scheme 7. Preparation UCNPs with a mesoporous silica shell impregnated with Roussin's Black Salt (red dots), a 417 
photo active nitric oxide generator, and coated with poly(allylamine).  NIR irradiation leads to upconversion to 418 
wavelengths overlapping the RBS absorbance and NO uncaging (adapted from ref. 58) 419 
 420 
Summary: 421 
 This article has largely summarized studies at UCSB that have explored strategies for 422 
photochemical uncaging of the nitric oxide for potential therapeutic applications.  Described are 423 
studies with NO precursors coupled to antennas consisting of organic dyes or nanoparticles and 424 
utilizing both single and multiple photon excitation.  The latter type of excitation offers the 425 
opportunity to use near-infrared light to access excited states that would otherwise require visible 426 
or ultraviolet light. NIR wavelengths are less damaging and will penetrate more deeply into 427 
mammalian tissue. The other advantage of multi-photon excitation is the non-linear intensity 428 
response of the induced photochemistry that offers the opportunity for three-dimensional 429 
resolution.   The use of lanthanoid ion doped upconverting nanoparticles as sensitizers for NIR 430 
uncaging appears particularly promising given that physiologically relevant concentrations of 431 
NO can be uncaged using a continuous NIR diode lasers.  The relatively low expense and the 432 
ease of operation and maintenance of such lasers would provide considerably greater access than 433 
the ultrafast pulsed lasers that were used to generate the intensities needed for simultaneous two 434 
photon excitation.  Nonetheless, it is clear that moving any such methods from the laboratory 435 
benchtop to therapy will be very challenging.    436 
Acknowledgement:  The studies described here have received long-term support from the 437 
Chemistry Division of the US National Science Foundation (current grant CHE-1058794).  I 438 
thank the many graduate, undergraduate and postdoctoral scholars and collaborators who 439 
contributed to this research. 440 
 441 
 20 
References: 442 
[1]   P. C. Ford, J. Bourassa, B. Lee, I. Lorkovic, K. Miranda, L. Laverman, Coord. Chem. Rev. 443 
171 (1998) 185-202. 444 
[2]  A. D. Ostrowski, P. C. Ford, Dalton Trans (2009) 10660-10669.  445 
[3]  P. C. Ford, Acc. Chem. Res. 41 (2008) 190-200.  446 
[4]  R. D. Rimmer, H. Richter, P. C. Ford, Inorg. Chem. 49 (2010) 1180 –1185.  447 
[5] R. D. Rimmer, A. Pierri, P. C. Ford Coord. Chem. Rev., 256, (2012) 1509-1519. 448 
[6] A. E. Pierri, A. Pallaoro, G. Wu, P. C. Ford, J. Am. Chem. Soc. 134 (2012) 18197-18200. 449 
[7]  L.R. Makings, R. Y.  Tsien, , J. Biol. Chem. 269 (1994) 6282-6285.   450 
[8]  E. Tfouni, M. Krieger, B. R. McGarvey, D. W. Franco, Coord. Chem. Rev 236 (2003) 57-69.  451 
[9]  C. N. Lunardi, A. L. Cacciari, R. S. Silva, L. M. Bendhack, Nitric Oxide 15 (2006) 252-258.   452 
[10] M. J. Rose, P. K.  Mascharak, Coord. Chem. Rev. 252 (2008) 2093-2114.  453 
[11] S. Sortino, Chem. Soc. Rev.  39 (2010) 2903-2913.  454 
[12] E. Tfouni, F. G. Doro, A. J.  Gomes, R. S. da Silva, G. Metzker,  P. G. Zanichelli Benini, D. 455 
W. Franco, Coord. Chem. Rev. 254 (2010) 355-371. 456 
[13] U. Schatzschneider, Inorg. Chim. Acta  374 (2011), 19-23.   457 
[14] C. C. Romao, W. A. Blaettler, J. D.  Seixas, Chem. Soc. Rev.  41 (2012) 3571-3583. 458 
[15] K. L. Ciesienski, K. J. Franz. Angew. Chem. Int. Ed.   50 (2011) 814-824. 459 
[16] L. A. Ridnour, D. D. Thomas, C. Switzer, W. Flores-Santana, J. S. Isenburg, S. Ambs, D. D. 460 
Roberts, D. A. Wink Nitric Oxide  19 (2008) 73-76. 461 
[17] J. B. Mitchell, D. A., Wink, W. DeGraff,  J. Gamson, L. K. Keefer, M. C. Krishna, Cancer 462 
Res., 53 (1993) 5845-5848.  463 
[18] H. Yasuda, Nitric Oxide 19 (2008) 205-216 464 
[19] T. C. Bellamy, C. Griffiths, J. Garthwaite, J. Biol. Chem. 277 (2002) 31801-31807. 465 
[20] J. Bourassa, W. DeGraff, S. Kudo, D. A. Wink, J. B. Mitchell, P. C. Ford, J. Am. Chem. 466 
Soc. 119 (1997) 2853-2862. 467 
[21] R. Motterlini, A. Gonzales, R. Foresti, J. E. Clark, C. J. Green, R. M. Winslow, Circ. Res. 468 
83 (1998), 568-577. 469 
[22] L. E. Otterbein, B. S. Zuckerbraun, M. Haga, F. Liu, R. P. Song, A. Usheva, C. Stachulak, 470 
N. Bodyak, R. N. Smith, E. Csizmadia, S. Tyagi, Y. Akamatsu, R. J. Flavell, T. R. Billiar, E. 471 
Tzeng, F. H. Bach, A. M. K. Choi, M. P. Soares, Nature Med. 9 (2003) 183-190. 472 
[23] R. Motterlini, L. E. Otterbein, Nature Rev. Drug Discovery 9 (2010) 728-743 473 
[24] K. Katada, A. Bihari, S. Mizuguchi, N. Yoshida, T. Yoshikawa, D. D. Fraser, R. F. Potter, 474 
G. Cepinskas, Inflammation 33 (2010) 92-100. 475 
[25] Y. Caumartin, J. Stephen, J. P. Deng, D. Lian, Z. Lan, W. Liu, B. Garcia, A. M. Jevnikar, H. 476 
Wang, G. Cepinskas, P. P. W. Luke, Kidney Int. 79 (2011) 1080-1089 477 
[26] A. M. Smith, M. C. Mancini, S. Nie, Nature Nanotech. 4 (2009) 710-711.  478 
[27] C. F. Works, P. C. Ford, J. Am. Chem. Soc. 122 (2000) 7592-7593. 479 
[28] M. De Leo, P. C. Ford, J. Am. Chem. Soc. 121 (1999) 1980-1981. 480 
 21 
[29] C. L. Conrado, J. L. Bourassa, C. Egler, S. Wecksler, P. C. Ford, Inorg. Chem., 42 (2003) 481 
2288-2293. 482 
[30] C. L. Conrado, S. R. Wecksler, C. Egler, D. Magde, P. C. Ford, Inorg. Chem., , 43 (2004) 483 
5543-5549. 484 
[31] S. R. Wecksler, A. Mikhailovsky, D. Korystov, P. C. Ford, J. Am. Chem. Soc., 128 (2006) 485 
3831-3837. 486 
[32] A. D. Ostrowski, R. O. Absalonson, M. A. DeLeo, G. Wu, J. G. Pavlovich, J. Adamson, B. 487 
Azhar, A. V. Iretskii, I. L. Megson, P. C.  Ford, Inorg. Chem. 50 (2011) 4453-4462.  488 
[33] A. D. Ostrowski, S. J. Deakin, B. Azhar, T. W. Miller, N. Franco, M. M. Cherney, A. J. Lee, 489 
J. N. Burstyn, J. M. Fukuto, I. L. Megson, P. C. Ford J. Med. Chem. 53 (2009) 715-722. 490 
[34] F. DeRosa, X. Bu, P. C. Ford Inorg. Chem. 44 (2005) 4157-4165. 491 
[35] D. Neuman, A. D. Ostrowski, A. A. Mikhailovsky, R. O. Absalonson, G. F. Strouse, P. C. 492 
Ford   J. Am. Chem. Soc. 130 (2008) 168-175. 493 
[36] P. T. Burks, A. D. Ostrowski, A. A. Mikhailovsky, E. M. Chan, P. S. Wagenknecht and P. 494 
C. Ford J. Am. Chem. Soc. 134 (2012) . 495 
[37] W. Denk, J. H.  Strickler, W. W. Webb, Science 248 (1990) 73-76. 496 
[38] P. T. C. So, C. Y. Dong, B. R. Masters, K. M  Berland, Annu. Rev. Biomed. Eng. 2 (2000) 497 
399-429.   498 
[39] B. W. Pedersen, T. Breitenbach, R. W. Redmond, P. R. Ogilby. Free Rad. Res. 44 (2010) 499 
1383-1397.  500 
[40] G. S. He, L.-S. Tan, Q. Zheng, P. N. Prasad, Chem. Revs. 108 (2008) 1245-1330.  501 
[41] M. Rumi, S. Barlow, J. Wang, J. W. Perry, S. R. Marder, Adv Polym Sci.  213 (2008) 1–95.  502 
[42] S. Dayal, S., C. Burda, C. J. Amer. Chem. Soc. 130 (2008) 2890-2891. 503 
[43] Y. Liu, P. Chen, Z. H. Wang, F. Bian, L. Lin, S. J. Chang, G. G. Mu, Laser Physics, 19 504 
(2009) 1886-1890.  505 
[44] S. Wecksler, A. Mikhailovsky, P. C. Ford, P. C. J. Amer. Chem. Soc. 126 (2004) 13566-506 
13567.  507 
[45] S. Wecksler, A. Mikhailovsky, D. Korystov, F. Buller, R. Kannan, L.-S. Tan, P. C. Ford, 508 
Inorg. Chem. 46 (2007) 395-402.   509 
[46] Q. Zheng, A. Bonoiu, T. Y. Ohulchanskyy, G. S He, P. N. Prasad, Mol. Pharm. 5 (2008) 510 
389-98.   511 
[47] S. V. Eliseeva, J.-C. G. Bunzli, Chem. Soc. Rev. 39 (2010) 189-227. 512 
[48] F. Zhang, Y. Wan, T. Yu, F. Q. Zhang, Y. Shi, S. Xie, Y. Li, L. Xu, B. Tu, D. Y. Zhao, 513 
Angew. Chem. Int. Ed. 46 (2007) 7976-7979. 514 
[49] F. Wang, X. Liu, Chem. Soc. Rev. 38 (2009) 976-89.  515 
[50] X. Wang, J.  Zhuang, Q. Peng, Y. Li,. Nature 437 (2005) 121-214.  516 
[51] G. S. Yi, G. M. Chow, Adv. Funct. Mater. 16 (2006)  2324–2329.  517 
[52] A. D. Ostrowski, E. M. Chan, D. J. Gargas, E. M. Katz, G. Han, P. J.  Schuck, D. J. 518 
Milliron, B. E. Cohen, ACS Nano 6 (2012) 2686–2692.  519 
[53] F. Wang, J. Wang, X. Liu, Angew. Chem. Int. Ed. 49 (2010) 7456 –7460. 520 
[54] G.-S. Yi, G.-M Chow, Chem. Mater. 19 (2007) 341–343.  521 
 22 
[55] H. S. Qian, H. C. Guo, P. C. L. Ho, R. Mahendran, Y.  Zhang,  small  5 (2009) 2285–2290.  522 
[56] C. J. Carling, F. Nourmohammadian, J. C. Boyer, N. R. Branda, Angew. Chem. Int. Ed. 49 523 
(2010) 3782 –3785.   524 
[57] Y. Yang, Q. Shao, R. Deng, C. Wang, X. Teng, K. Cheng, Z. Cheng, L. Huang, Z. Liu, X. 525 
Liu, B. Xing, Angew. Chem. Int. Ed. 51 (2012) 3125 –3129.  526 
[58] J. V. Garcia, J. Yang, D. Shen, C. Yao, X. Li, G. D. Stucky, D. Y.  Zhao, P. C. Ford, F. 527 
Zhang, Small, 8 (2012) 3800–3805  528 
[59] F. W. Flitney, I. L. Megson, J. L. M. Thomson, G. D. Kennovin, A. R. Butler, Br. J. 529 
Pharmacol., 117 (1996) 1549-1557.   530 
[60] J. L. Bourassa, B. Lee, S. Bernard, J. Schoonover, P. C. Ford,  Inorg. Chem. 38 (1999) 531 
2947-2952.  532 
 533 
